CHRNA9 rs56159866, rs6819385, rs55998310, and rs182073550 SNPs were genotyped and associated for NSCLC risk by computing the odds ratios (ORs) and 95 % confidence intervals (CIs) from multivariate unconditional logistic regression analyses with adjustment for age.
The CHRNA9 rs6819385 A/A homozygote was associated with an increased risk of NSCLC</span> an</span>d SCC in all patients (OR = 1.38; 95% CI 1.06-1.79; P = 0.02, and OR = 1.61; 95% CI 1.09-2.38; P = 0.02, respectively) and in male patients (OR = 1.57; 95% CI 1.11-2.21; P = 0.01, and OR = 1.70; 95% CI 1.11-2.61; P = 0.01, respectively), indicating that the CHRNA9 rs6819385 A/A homozygote had a 1.61-fold and 1.70-fold increased risk of developing lung SCC in all patients (95% CI 1.09-2.38, P = 0.02) and in males (95% CI 1.11-2.61, P = 0.01), respectively.
The CHRNA9 rs6819385 A/A homozygote was associated with an increased risk of NSCLC and SCC in all patients (OR = 1.38; 95% CI 1.06-1.79; P = 0.02, and OR = 1.61; 95% CI 1.09-2.38; P = 0.02, respectively) and in male patients (OR = 1.57; 95% CI 1.11-2.21; P = 0.01, and OR = 1.70; 95% CI 1.11-2.61; P = 0.01, respectively), indicating that the CHRNA9 rs6819385 A/A homozygote had a 1.61-fold and 1.70-fold increased risk of developing lung SCC in all patients (95% CI 1.09-2.38, P = 0.02) and in males (95% CI 1.11-2.61, P = 0.01), respectively.
A SNP in the alpha9 subunit, the G allele of rs10009228 (alpha9, A>G) shows a significant trend in the combined cohort, indicating that this allele constitutes a risk factor for neoplastic progression.
We found nominally significant (P<0.05) allelic and genotypic association with smoking initiation of SNP rs2072660 and multilocus haplotypes (P<0.007-0.05) in CHRNB2 and nominal (P<0.05) allelic or genotypic association of SNPs in CHRNA7 (rs1909884), CHRNA9 (rs4861065) and CHRNB3 (rs9298629) with nicotine dependence.